Valuation: Novavax, Inc.

Market Cap 174.84Cr 155.49Cr 145.27Cr 132.5Cr 248.67Cr 17TCr 252.38Cr 1.76TCr 680.4Cr 8.58TCr 656.41Cr 642.13Cr 28TCr P/E 2026 *
-17x
P/E 2027 * -47.3x
Enterprise Value 196.74Cr 174.97Cr 163.46Cr 149.09Cr 279.82Cr 19TCr 283.99Cr 1.98TCr 765.62Cr 9.66TCr 738.63Cr 722.56Cr 31TCr EV / Sales 2026 *
5.28x
EV / Sales 2027 * 7.71x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day-1.94%
1 week+0.47%
Current month-1.94%
1 month+13.13%
3 months+12.53%
6 months+30.22%
Current year+57.74%
1 week 10.26
Extreme 10.26
11.11
1 month 9.11
Extreme 9.11
11.11
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
236.5
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/06/26 Exercice

Director

37,760 0.0230%
18/06/26 Free

Director

35,450 0.0216%
25/04/26 Exercice

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
-1.94%+0.47%+22.26%+46.41% 178.31Cr
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.61%+0.69%+36.36%+82.72% 6.01TCr
-2.54%-0.21%+6.34%+31.72% 4.82TCr
-3.02%-2.67%+37.26%+32.51% 4.43TCr
+0.31%+7.94%+340.88%+643.82% 4.4TCr
-1.96%-1.71%+5.30%+99.46% 4.16TCr
+3.32%+3.49%+11.18%+51.23% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-4.86%-8.24%-24.60%+330.06% 2.49TCr
Average -0.24%+2.01%+52.11%+143.49% 3.99TCr
Weighted average by Cap. +0.16%+1.83%+59.90%+145.33%

Financials

2026 *2027 *
Net sales 37Cr 33Cr 31Cr 28Cr 53Cr 3.59TCr 54Cr 374.63Cr 145.13Cr 1.83TCr 140.02Cr 136.97Cr 5.89TCr 27Cr 24Cr 22Cr 20Cr 38Cr 2.56TCr 38Cr 267.38Cr 103.58Cr 1.31TCr 100Cr 98Cr 4.2TCr
Net income -11Cr -9.56Cr -8.94Cr -8.15Cr -15Cr -1.04TCr -16Cr -108.03Cr -42Cr -527.99Cr -40Cr -39Cr -1.7TCr -3.79Cr -3.37Cr -3.15Cr -2.87Cr -5.39Cr -365.28Cr -5.47Cr -38Cr -15Cr -186.2Cr -14Cr -14Cr -598.79Cr
Net Debt 22Cr 19Cr 18Cr 17Cr 31Cr 2.11TCr 32Cr 219.99Cr 85Cr 1.08TCr 82Cr 80Cr 3.46TCr 30Cr 27Cr 25Cr 23Cr 43Cr 2.92TCr 44Cr 304.58Cr 118Cr 1.49TCr 113.84Cr 111.36Cr 4.79TCr
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
01/26/01 $10.60 -1.94% 31,43,473
30/26/30 $10.81 -0.09% 45,65,584
29/26/29 $10.82 +0.19% 40,71,340
28/26/28 $10.80 +1.60% 44,61,695
25/26/25 $10.63 +0.28% 39,10,299
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.60USD
Average target price
14.00USD
Spread / Average Target
+32.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock